Clinical Trials
8 trialsNCT07095452 2026-05-27
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT04513639 2025-03-20
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Oslo University Hospital
Phase 2/3 Recruiting
NCT06879379 2025-03-17
KPD Consolidation After ASCT in NDMM Patients
Peking University People's Hospital
Phase 2/3 Recruiting
NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT00038090 2018-10-31
Thalidomide-Dexamethasone for Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT02419118 2017-11-07
DARA
Vejle Hospital
Phase 2/3 Completed
NCT00861250 2016-06-17
Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
Tampere University Hospital
Phase 2/3 Completed